1 . Interestingly, recent data suggests that staurosporine can inhibit tumor growth in a number of systemic malignancies.
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. It also increases the translocation of cytochrome c to the cytoplasm and has an enhancing effect on intra-tumoral apoptosis. As a result it markedly decreases tumor growth in prostate malignancies. Besides this, staurosporine also up-regulates the expression of TIMP-1 as a result of increased transcription. This further attenuates tumor invasiveness. Staurosporine also causes increased expression of tau in the cancerous cells 8 . As a result staurosporine increases differentiation of the cancerous cells to cells with neuronal features. As a consequence, tumor invasiveness is attenuated by as much as 20%. It also augments PARP inactivation at the same time 9 .
Similar effects are seen in non-small cell lung carcinomas. Staurosporine augments the activity of thymidine kinase-2 within the tumor 4 . As a result, it increases the chemo-sensitivity of lung tumors to chemotherapeutic agents such as gemcitabine and cisplatin. dCK activity is also increased simultaneously while E2F expression is decreased. At the same time, staurosporine down-regulates RNR expression 7 . Retinoblastoma gene product expression is also altered by staurosporine 5 . Similar effects are seen in gastrointestinal malignancies such as gastric carcinomas. Staurosporine administration results in up-regulation of the p21WAF1 gene 6 . As a result, there is augmented G2/ M phase arrest. Apoptosis is markedly increased. As a result tumor growth is markedly attenuated.
The above examples clearly illustrate the significant anti-proliferative and apoptotic features of staurosporine and the need for further studies to explore and harness its anti-neoplastic effects. 
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